Resistance of

Nasser Mostafavi, Moein Bighamian, Sina Mobasherizade, Roya Kelishadi

Abstract read

In one paragraph

Article in Medical journal of the Islamic Republic of Iran. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

0.9field-weighted citation impact, top 23% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

Determination of ESBLs, pAmpC-beta-lactamase genes, and plasmid replicon types amongArchives of Razi Institute · 2025
Article
Methodology and Early Results of the First Surveillance Program on Prevention and Control of Antimicrobial Resistance in Isfahan, Iran: The IAS-I Study.International journal of preventive medicine · 2020
Article
Prevalence and antimicrobial resistance ofInfection and drug resistance · 2019
Article
Increasing clinical resistance rate ofAnnals of translational medicine · 2018
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nasser MostafaviMD, Assistant Professor, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. n_mostafavy@med.mui.ac.ir.

Moein BighamianMedical student, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran. mb.baran1920@yahoo.com.

Sina MobasherizadePhD of Microbiology, Nosocomial Infections Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. mobasherizadeh@gmail.com.

Roya KelishadiMD, Professor, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran. roya.kelishadi@gmail.com.

Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CiprofloxacinIranShigellosisSusceptibilityThird Generation Cephalosporin

Identifiers

PMID28210593

PMCPMC5307619

OpenAlexW2547480770

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.